Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors - Takeaways - MDSpire

Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors

  • By

  • Darren Hargrave

  • Lynley V. Marshall

  • Nicolas André

  • Julie Krystal

  • Brian H. Ladle

  • Karen A. Robbins

  • Stephan Hois

  • Jon Armstrong

  • Sarah Donegan

  • May 15, 2026

Share

  • 1

    The study evaluated durvalumab and tremelimumab in pediatric patients with relapsed/refractory solid tumors.

  • 2

    The recommended phase II dose was determined as durvalumab 30 mg/kg and tremelimumab 1 mg/kg based on safety data.

  • 3

    In the dose-expansion phase, limited antitumor activity was observed, with one patient achieving a partial response.

  • 4

    76% of patients experienced treatment-related adverse events, but no deaths were reported due to these events.

  • 5

    The combination therapy had a manageable safety profile consistent with adult data, with no new safety concerns identified.

Original Source(s)

Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors

  • by Darren Hargrave, Lynley V. Marshall, Nicolas André, Julie Krystal, Brian H. Ladle, Karen A. Robbins, Stephan Hois, Jon Armstrong, Sarah Donegan

  • May 15, 2026

Related Content

Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers?

A systematic review and meta-analysis found that early time-of-day immunotherapy was associated with improved survival outcomes in patients with advanced cancers, with the association appearing to be ...

Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC

In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonge...

Lack of Research in Understanding the Global Population of Childhood Cancer Survivors Leads to Gaps in Care and Cures

Each year, globally, about 400,000 children and adolescents aged between 0 and 19 years are diagnosed with cancer; over 100,000 die from the disease, with most of those cases, over 80%, and deaths occ...